ClinicalTrials.gg
CompletedNCT03452345Updated Jul 28, 2020

MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy

A Phase 3 interventional study of Meditoxin and Placebo in Masseter Muscle Hypertrophy, sponsored by Medy-Tox. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-07-28.

Sponsored by Medy-Tox · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of MEDITOXIN in subjects with benign masseteric hypertrophy compared with placebo

02

Conditions studied

  • Masseter Muscle Hypertrophy
03

In context

Lead sponsor

Medy-Tox is the lead sponsor of 49 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • subject who aged 20 to less than 65 years
  • subject with benign masseteric hypertrophy

Exclusion criteria

Exclusion Criteria:

  • subject not appropriate for participating in this study according to the investigator's opinion
  • subject with known an anaphylactic response to BoNT/A and other involved ingredients of product
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    MEDITOXIN

    Drug: Meditoxin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Meditoxin (Botulinum toxin type A)

  • DrugPlacebo

    Placebo (Normal saline)

06

What researchers measure

Primary outcomes

  1. changes in the thickness of the masseter muscle during maximum clenching measured using ultrasound at week 12 from baseline

    Time frame: 12 week follow-up visit

Secondary outcomes

  1. changes in the thickness of the masseter muscle as usual measured using ultrasound at week 12 from baseline

    Time frame: 12 week follow-up visit

07

Study locations

1 site
  • Kangbuk Samsung Hospital
    Seoul, 03181, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jan 2019, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2018
First posted
Mar 2, 2018
StartActual
Apr 9, 2018
Primary completionActual
Jan 31, 2019
CompletionActual
Apr 16, 2019
Last update
Jul 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03452345
Lead sponsor
Medy-Tox
Responsible party
Sponsor
First posted
Mar 2, 2018
Start date
Apr 9, 2018
Primary completion
Jan 31, 2019
Completion
Apr 16, 2019
Last update
Jul 28, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Botulinum toxin type A

Start the discussion